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Background: The extent of episodic diarrhoea in the community is relatively 
unknown.  
Aim: To ascertain the prevalence, symptoms and management behaviours 
associated with self-reported diarrhoea across 11 countries. 
Methods: Community screening surveys were conducted using quota sampling 
of respondents to identify a nationally representative sample of individuals 
suffering from ‘episodic’ diarrhoea (occurring once a month or more often). 
Second-phase in-depth surveys provided data on epidemiology, symptoms, 
attributed causes and management of episodic diarrhoea. 
Results: A total of 11,508 phase 1 and 6,613 phase 2 surveys were completed. 
The prevalence of self-reported episodic diarrhoea ranged from 16% to 23% 
across the 11 countries. The majority of episodic diarrhoea sufferers were 
female (57%) and were not diagnosed with pre-existing irritable bowel 
syndrome (IBS); IBS diagnosis ranged from 9% in Mexico to 44% in Italy. 
Diarrhoea was frequently attributed to anxiety/stress, food-related causes, 
gastrointestinal “sensitivity” and menstruation. Accompanying symptoms 
included “stomach pain/cramping” (35–62%), “stomach grumbling” (29–68%) 
and “wind” (18–74%). The proportion of episodic sufferers who reported treating 
their symptoms with remedies or medications ranged between 46% in Belgium 
and Canada and 90% in Mexico. 
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Conclusion: A substantial proportion of the population in middle- to high-income 
countries report episodic diarrhoea in the absence of a pre-existing diagnosis. 
These symptoms are likely to be associated with substantial social and 
economic costs and have implications on how best to configure and guide self-
led, pharmacist-led and primary care management. 
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Introduction 
Diarrhoea in adults is a common complaint and, while rarely life-threatening 
outside of developing countries, it continues to be an important cause of 
morbidity.1 Symptoms can cause distress and incapacitate sufferers,2 
significantly impacting on health-related quality of life.3 The precise clinical 
presentation, time course and management requirements are dependent on the 
underlying pathological determinants. Current guidelines classify diarrhoea as 
either acute1,2,4 or chronic.5,6 No universally accepted definition is available, but 
acute diarrhoea has been described as the passage of a greater number of 
stools of decreased form lasting less than 14 days4 and, more recently, defined 
by the World Gastroenterology Organisation as three or more loose stools in 
the preceding 24 hours.1 Acute cases of diarrhoeal illness are usually brief and 
self-limiting2 and are commonly treated without consultation with a health 
professional.7 Thus, assessment of acute diarrhoea prevalence requires 
specialised community-based cohort studies or population-based surveys.7 
Previously, the rate of diarrhoeal illness (three or more loose stools in a 24-hour 
period causing impairment of daily activities or diarrhoea duration greater than 
1 day) and/or vomiting in industrial countries has been estimated at around one 
episode every 18 months (0.65 episodes per person-year).7  
Chronic or persistent diarrhoea is usually defined as the abnormal passage of 
three or more loose stools per day lasting longer than 4 weeks.5,6 It is estimated 
that 3–5% of the population may have diarrhoea lasting more than 1 month in 
any given year.6 
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The distinction between acute and chronic diarrhoea has important implications 
for management. Most patients with diarrhoea lasting more than 4 weeks will be 
found to have a non-infectious cause, whereas acute, self-limiting, 
uncomplicated cases of diarrhoea are generally assumed to be infectious in 
nature.6  
There is a paucity of data evaluating diarrhoea prevalence and causes in the 
community. In reality, there is likely to be a population who experience recurrent 
diarrhoea symptoms of limited duration, but who do not fit easily into the 
classically defined categories of ‘acute’ or ‘chronic’. To further understand the 
impact of self-reported diarrhoea symptoms, we took a two-fold approach to 
investigate this in the general adult population of 11 middle-to high-income 
countries. Phase 1 of this study determined the prevalence of self-reported 
diarrhoea symptoms occurring once monthly or more often among adults, and 
phase 2 sought insights into symptoms and behaviours among individuals 
reporting episodes monthly or more often. 
Methods 
Survey and subjects 
The results from online surveys in 11 countries administered to a total of 
11,508 participants are reported here (Table 1). The surveys were originally 
carried out in 13 countries and, while the surveys shared a common basic 
theme, they were conducted on an individual basis within each country, with 
some national variation in questionnaire format and approaches to data 
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collection and analysis. Data from the UK and Russia were excluded owing to 
methodological differences that may have influenced survey responses. In the 
UK, episodic diarrhoea was defined differently (4 times in 6 months); surveys in 
Russia were administered by telephone interviews rather than self-
administration online. 
The surveys used an established research methodology for large scale data 
collection, with predetermined numbers in age and sex bands, to create a more 
representative sample than would be obtained by conventional methods such 
as household surveys or locally administered questionnaires. This approach 
has been used effectively in previous gastrointestinal research.8,9  In each of 
the 11 countries reported here, samples of adults from a market research panel 
were invited by email to complete a self-administered online survey. Market 
research panels are composed of pre-recruited individuals who have agreed to 
participate in online market research surveys. Several methodologies are used 
for recruitment, such as opt-in email, co-registration, electronic newsletter 
campaigns, and traditional banner placements. Research panels use several 
panel recruiting partners to build high quality panels with a varied sample 
population that can provide robust sample sizes. Panels measure recruitment 
sources on multiple metrics to track both activity and engagement by 
demographic group. Hundreds of profiling attributes are monitored to ensure 
that the panel population is representative of the national population.  
Panellists, aged between either 16 or 18 and 64 years (Table 1), were randomly 
invited to participate in the survey. Invitations were issued blind; no information 
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was provided about the subject of the survey or who commissioned the 
research. To prevent duplication, survey links could only be used once. Quotas 
were applied to ensure national representativeness for age and gender and 
cells were filled on a first-come, first-served basis. Whilst quotas were used to 
achieve a representative sample, there were instances when insufficient 
response rates meant quota cells could not be filled. When this occurred 
weighting was applied to the data set to account for over- or under-
representation of the demographic groups in the data set.  
Any respondent who had completed a project of a similar nature in the previous 
3 months or who was associated with advertising, market research, marketing, 
journalism, or the pharmaceutical industry, was excluded. The questionnaire 
was drafted in English and then translated professionally  into relevant local 
languages. To validate questionnaire wording and routing, pilot interviews were 
conducted among a sample of respondents.  
A specialist market research company, Incite (London, UK), was responsible for 
the development and undertaking of the online survey and collation of data. All 
surveys were conducted in accordance with the Market Research Society 
(MRS) guidelines. 
Survey questions and application 
The phase 1 survey was designed to establish demographic data and to identify 
individuals experiencing diarrhoea once monthly or more. The phase 2 survey 
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was designed to determine the perceived causes of diarrhoea, accompanying 
symptoms, and action taken in response to diarrhoea symptoms. 
In phase 1, participants were asked how often they suffered from several 
problems including constipation, headache, vomiting, heartburn/indigestion and 
diarrhoea (“urgent, frequent, loose or watery stools”). In all countries prevalence 
was assessed using the following frequency of suffering question: 
Q: How often do you suffer from each of the problems in the table below? 
Diarrhoea (urgent, frequent, loose or watery stools) 
      1) Never 
      2) Less often 
      3) Once every 12 months 
      4) Once every 4–6 months 
      5) Once every 2–3 months  
      6) Once a month 
      7) 2–3 times a month 
      8) Once a week 
      9) More than once a week 
 
Phase 2 survey links were then sent to individuals recruited from a market 
research panel who were targeted based on the specific demographic profile of 
individuals with  once monthly or more often diarrhoea identified in phase 1 (in 
Canada, France and Italy, participants from phase 1 who selected options 6–9 
were also invited to complete the phase 2 survey). In all countries, the frequency 
question was asked at the start of the phase 2 questionnaire to ensure all 
respondents experienced diarrhoea monthly or more often. A link to the survey was 
sent out to individuals with incentives for completion (vouchers or a prize draw).  
Data analysis 
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All analyses were conducted using the statistical analysis software, SPSS. For 
quality control, data were checked for flat-liners (respondents who tended to give 
an average rating for all answers, suggesting that they were not really reading the 
question and/or answering it without much thought), and for respondents who 
completed the survey in a significantly faster time than would be expected or who 
gave inconsistent responses. These respondents were excluded according to 
standard research practice.  
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Results  
Diarrhoea prevalence 
A total of 11,508 phase 1 surveys were completed (Table 1); questions in this 
section determined if participants suffered from diarrhoea and how often. Phase 2 
interviews were then completed by 6,613 individuals who reported experiencing 
diarrhoea once a month or more often. For the purpose of this manuscript, 
individuals who completed the phase 2 survey (reporting diarrhoea frequency of at 
least once a month) will be described as having ‘episodic’ diarrhoea.  
The prevalence of self-reported episodic diarrhoea ranged from 16% to 23%. In 10 
of the 11 countries, the prevalence was between 16% and 19% (Figure 1). Using 
data from the frequency of suffering question (see methods), the number of 
episodes that each phase 1 respondent would suffer in a 6-month period was 
calculated (assuming mid-points for ranges, e.g. once every 4–6 months = once 
every 5 months or 1.2 episodes in 6 months). This revealed that diarrhoea 
episodes experienced by the episodic diarrhoea sub-population accounted for 77% 
to 91% of the total self-reported episodes. In most countries, respondents with 
episodic diarrhoea experienced between three and four episodes per month 
(Figure 2). Weekly or more often symptoms were reported by 4% to 6% of phase 2 
respondents in all 11 countries.  
Episodic diarrhoea population  
The age distribution of the sample in each country was similar for the entire survey 
population and those with episodic diarrhoea. However, compared with the total 
survey population (48%–49% female in each country), there was a trend for the 
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gender distribution of episodic sufferers to favour females (43.2% male, 56.8% 
female; Figure 3).  
Episodic sufferers claiming to have been diagnosed with irritable bowel syndrome 
(IBS question: “Have you been diagnosed with irritable bowel syndrome by your 
doctor?”) ranged from 9% to 44% (Canada 21%, Belgium 35%, Australia 24%, 
France 38%, Germany 28%, Italy 44%, Sweden 18%, Finland 12% and Mexico 
9%; question not asked in Spain and Argentina). 
Symptoms and attributed causes 
Participants were asked about symptoms experienced during a diarrhoea episode 
(question: “Which of the following problems, if any, did you suffer from at the 
time?”). Frequently reported symptoms accompanying diarrhoea (Table 2) included 
“stomach pains/cramping” (35% to 62%), “stomach grumbling” (29% to 68%) and 
“wind” (18% to 74%). 
The precise questions relating to attributed causes of diarrhoea varied between 
countries. For example, most questionnaires asked, “Which of the following do you 
think can cause diarrhoea for you?”, while those in Canada, Australia and Belgium 
specified causes on the last occasion and asked, “What do you think was the 
cause of the problems you were suffering from on this [last] occasion?”. Although 
there was also some variation in the provided list of options for participants to 
choose from, there were some clear trends. In all countries except Mexico, 
“nerves, anxiety or stress“ was among the three most commonly reported causes 
(18% to 65%). In Mexico, the top three causes were “eating certain foods”, “food 
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intolerance” and “excessive food”. Food-related causes were also frequently cited 
in the other countries. In seven countries where “eating certain foods“ was an 
option, it was among the three most commonly reported causes, while “I have a 
sensitive system” was among the three most common causes in seven out of 10 
countries where this was asked. Food intolerance (9% to 53%) and/or IBS (5% to 
35%) were also frequently reported, while “chronic illness (such as Crohn’s disease 
or ulcerative colitis)” was less frequently cited (5% to 11%).  
In European countries where respondents were asked about their usual cause of 
diarrhoea, menstruation was reported among women at rates between 24% and 
43% (Germany 31%, France 24%, Italy 36%, Finland 38% and Sweden 43%), but 
was reported less commonly as a cause in Argentina (4%) and Mexico (18%) and 
countries reporting “last occasion” cause of diarrhoea: Belgium (12%), Australia 
(11%) and Canada (12%). 
Symptom treatment 
Phase 2 participants were asked about treatment of symptoms (Figure 4; example 
question: “In the last 6 months on the occasions when you have had diarrhoea, 
which of these things have you done at all”). In most countries the majority of 
episodic diarrhoea sufferers reported taking something to treat their symptoms 
during the last 6 months (list provided contained prescription, over-the-counter 
[OTC] and natural/non-chemical products). Belgium and Canada had the highest 
proportion of individuals who did not use a product to treat their symptoms (54%); 
Mexico exhibited the lowest proportion (10%). Among those who treated their 
symptoms, the proportion that used a prescription or an OTC product in the last 6 
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months was between 69% and 92%, with the exception of Germany (45%) and 
Finland (49%), which had the highest proportion of episodic diarrhoea respondents 
who used home remedies/natural products (Figure 5). The use of home 
remedies/natural products was lower in France, Mexico and Argentina compared 
with other countries. 
 
In  9 countries where participants were asked, “Earlier you said you sometimes 
experience diarrhoea and do nothing, why is that?” there was some consistency in 
the most common reasons for not treating. Frequently reported reasons were “I 
generally avoid taking medicines” (15% to 42%), “the diarrhoea goes away quite 
quickly” (15% to 65%) and “I don’t get diarrhoea too severely” (25% to 62%). 
Although respondents did not commonly believe treatments were bad for them (0% 
to 10%), in many cases respondents indicated that they thought they should not 
interfere with the diarrhoeal process, by selecting options such as, “I prefer to let 
nature take its course” (31% to 44%), “purifying effect is positive” (8% to 27%) and 
“I don’t want to interfere with flushing out bugs and toxins” (7% to 20%). 
 
Discussion 
While diarrhoea is a common problem in developing countries, largely attributed to 
infection, the extent of the problem in the community of higher- and middle income 
countries is largely unknown. A proportion of such sufferers will have had short-
lasting episodes of infectious diarrhoea, but there is also likely to be a group of 
sufferers who do not have a diagnosed clinical problem, such as IBS or 
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inflammatory bowel disease, but who are prone to diarrhoea from time to time. The 
gastrointestinal burden in UK primary care is approximately 10% of all 
consultations, around half of which are related to lower gastrointestinal problems.10 
In addition, there exists a reservoir of people who do not consult but many of 
whom, nonetheless, have troublesome symptoms. Thus, quantifying the size of the 
potential problem is important, both to inform management strategies and to 
provide opportunities for effective interventions where needed.  
To the best of our knowledge, the prevalence of self-reported diarrhoea symptoms 
occurring episodically in the community setting has not been previously 
ascertained. We used an established market research-based methodology to 
reach out to large numbers of respondents in an international setting, ensuring 
adequate numbers in each country, representative of the adult population to the 
age of 65 years. Representative surveys are ideal for assessing the prevalence of 
this type of symptom across whole populations, overcoming the disadvantages of 
smaller scale, household or locality-based surveys and providing valuable data for 
clinical use.8,9,11 Online methodology allows data to be collected across a wide 
geographical area, avoiding the limitations of postal services, and is less 
susceptible to embarrassment and interviewer bias compared with face-to-face 
interviews.12 
A weakness of this type of market research survey is that the standard age cut-off 
is 65 years and, thus, our results are only of relevance to the sub-65-year 
population. However, US surveillance reveals that adults over the age of 65 years 
have the lowest rates of self-reported acute diarrhoeal illness.13 Another limitation 
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to the applied survey methodology was that the respondents were not asked 
directly about the severity or duration of their symptoms, although the fact that in 
many countries the majority of sufferers reported treating their symptoms indicates 
that they were of sufficient severity and/or inconvenience to warrant intervention. 
Previous research has confirmed that variations exist between countries in the 
prevalence of some gastrointestinal disorders, and that females are more likely to 
have been diagnosed.14 To some extent these findings may reflect national and 
cultural differences in consultation behavior and health care systems; 15,16 our 
findings are likely to be associated with similar factors.  
The survey confirmed that there is a large ‘hidden’ population of adult diarrhoea 
sufferers who report episodes of diarrhoea occurring at least once a month. The 
importance of this population is underlined by the fact that the overwhelming 
majority of all self-reported episodes of diarrhoea are experienced by adults with 
episodic diarrhoea. Episodic diarrhoea was reported more frequently by females 
and was commonly accompanied by symptoms such as “stomach cramping or 
grumbling” and “wind”. Those suffering from episodic diarrhoea perceived their 
causes to be mostly psychological and food-related rather than an underlying 
chronic condition. Menstruation was also a major factor, with the proportion of 
women reporting it as a trigger for episodic diarrhoea being relatively high in some 
European countries.  
Diarrhoea is a major feature in IBS15 and the proportion of respondents with 
episodic diarrhoea claiming to have been diagnosed with IBS ranged between 9% 
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and 44%. However, it is not possible to predict how much of the burden of self-
reported diarrhoea is related to undiagnosed functional bowel disease as many 
patients are likely not to have had a formal diagnosis. A previous pan-European 
survey reported IBS prevalence (diagnosed and undiagnosed combined) ranging 
from 6% to 12%,9 with one-fifth meeting the Rome II criteria for diarrhoea-
predominant IBS and two-thirds having alternating (diarrhoea/constipation) IBS. 
The prevalence of episodic diarrhoea in the current survey was generally greater, 
ranging between 16% and 19% in most countries.  
Similarities between the respondents with episodic diarrhoea in our survey and IBS 
populations identified in previous surveys were noted. For example, IBS is also 
reported to be more prevalent in women, with an international prevalence that is 
67% higher than in men or an absolute difference in prevalence of around 5% 
between the sexes (14.0% in women compared with 8.9% in men).14 Furthermore, 
food and stress have been reported by IBS patients as major triggers for their IBS 
episodes.8 Therefore, it seems likely that IBS (and potentially other conditions such 
as coeliac disease and inflammatory bowel disease) may be contributing to 
episodic diarrhoea. However, this cannot account for the entire population with 
episodic diarrhoea, and it is likely that a significant proportion of these patients 
would not meet the criteria for diagnosis with IBS or have chronic organic 
conditions responsible for their symptoms. It is also likely that a proportion of 
patients with episodic diarrhea have either been diagnosed by their physicians as 
having IBS, or meet the diagnostic criteria in the absence of a formal diagnosis. 
Previous infectious gastroenteritis and/or traveller’s diarrhoea [DuPont 2009] are 
Hungin et al. 
 
17 
 
known risk factors for the development of so-called post-infectious-IBS, a long-term 
condition of altered stool form and abdominal pain.[Thabane 2007;Schwille-kiuntke 
2015] It would be intriguing to determine if previous enteric infection is also a risk 
factor associated with episodic diarrhoea. 
In most countries, the majority of those with episodic diarrhoea claim to have used 
some form of remedy or medication. Reported reasons for non-treatment of 
symptoms suggested that some sufferers with diarrhoea may benefit from more 
comprehensive, evidence-based advice on self-treatment. While some 
respondents reported that they generally avoided taking medicines or preferred to 
let nature take its course, responses such as, “I don’t want to interfere with flushing 
out bugs and toxins” indicates that some individuals may not be taking the 
opportunity to relieve the discomfort or the social dysfunction associated with 
diarrhoea because of misconceptions about diarrhoea and available treatments.2 
While there is a need to avoid unnecessary medicalisation and, indeed, in many 
sufferers symptoms may not be sufficiently significant to warrant further 
investigation , health providers need to be aware of this undefined group. There 
are parallels in consultation behavior between episodic diarrhoea and travellers’ 
diarrhoea, a common and well-recognised complaint17 for which people are only 
likely to seek medical attention if the symptoms are persistent or severe. 
Nonetheless, episodic diarrhoea symptoms are likely to represent costs in 
suffering, productivity loss and other economic costs such as expenditure on 
remedies and medications. Some will benefit from a clinical assessment and a 
possible diagnosis to improve their wellbeing. Thus, a better understanding of the 
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extent, patterns and causes of episodic diarrhoea may help to enhance self and 
health professional management, facilitating better strategies for this latent group. 
Further research to ascertain the impact on sufferers and the value of targeted 
management strategies is required. This should include reviewing current 
pharmacist-led approaches and improving awareness and education in community 
and primary care.  
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Table 1. Age and gender distribution among those that completed self-
administered surveys in 11 countries. Phase 1 surveys were carried out 
among a nationally representative sample of the population. Phase 2 surveys 
were carried out among individuals identified as having episodic diarrhoea. 
*Included panellists from age 16. †Upper age bands represent 45–49 and 50–64 
years. 
 
Figure 1. Prevalence of self-reported diarrhoea occurring once monthly or 
more often. Phase 1 participants were asked, “How often do you suffer from 
each of the problems in the table below?”. The percentage of respondents that 
reported experiencing “diarrhoea (urgent, frequent, loose or watery stools)” at a 
rate of either “once a month”, “2-3 times a month”, “once a week” or “more than 
once a week” are shown. 
 
Figure 2. Average number of episodes per month among those with 
diarrhoea occurring once monthly or more often. Phase 1 participants were 
asked, “How often do you suffer from each of the problems in the table below?”. 
The frequencies of those reporting diarrhoea (urgent, frequent, loose or watery 
stools) were used to estimate the number of episodes per month. 
 
Figure 3. The gender distribution among those reporting diarrhoea once 
monthly or more often. Percentage of male and female respondents with 
episodic diarrhoea in each country. 
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Table 2. Self-reported symptoms secondary to diarrhoea occurring once 
monthly or more often. Participants with episodic diarrhoea were asked about 
symptoms on the last occasion they had diarrhoea, “Which of the following 
problems, if any, did you suffer from at the time?”. Respondents were 
presented with a list of possible symptoms and asked to select all those that 
applied. Symptoms other than diarrhoeal symptoms (diarrhoea, an urgent need 
to go to the toilet, loose or watery stools, slack stools/unbalanced transit) are 
presented here. 
Question not asked in Spain or Argentina. Empty cells (–) indicate symptom 
was not included in the questionnaire of that country. 
 
Figure 4. Treatment of symptoms among those with diarrhoea occurring 
once monthly or more often  
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Responses to the question, “In the last 6 months on the occasions when you 
have had diarrhoea, which of these things have you done at all?. 
Respondents were presented with a list of options such as “Took an over-the 
counter diarrhoea medication obtained directly from a pharmacy without a 
prescription”, “Took a non-chemical health product designed to help with 
diarrhoea” or “Experienced diarrhoea and did nothing”. Data is split into 
respondents who took something versus those who did nothing. 
The Spanish survey asked about treatment over a 12-month period; all other 
countries were 6 months. 
 
Figure 5. Type of treatments used among those treating diarrhoea 
symptoms occurring once monthly or more often. 
Responses to the question, “In the last 6 months on the occasions when you 
have had diarrhoea, which of these things have you done at all?”  
Respondents were presented with a list of options such as “Took an over-the 
counter diarrhoea medication obtained directly from a pharmacy without a 
prescription”, “Took a non-chemical health product designed to help with 
diarrhoea” or “Did nothing”. They were asked to select all that apply. Data are 
split into respondents who took prescription or over-the-counter (OTC) 
medication versus those that took other types of remedies. 
The Spanish survey asked about treatment over a 12-month period; all other 
countries were 6 months. 
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studies  
 
Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in 
the title or the 
 abstract    
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found  
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported  
Objectives 3 State specific objectives, including any prespecified 
hypotheses  
Methods 
Study design 4 Present key elements of study design early in the paper  
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants  
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable  
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group  
Bias 9 Describe any efforts to address potential sources of bias  
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
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(b) Describe any methods used to examine subgroups and 
interactions 
(c) Explain how missing data were addressed  
(d) If applicable, describe analytical methods taking account of 
sampling strategy 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-
up, and analysed  
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders 
(b) Indicate number of participants with missing data for each 
variable of interest 
Outcome data 15* Report numbers of outcome events or summary measures  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included 
(b) Report category boundaries when continuous variables 
were categorized 
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives  
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias  
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence  
Generalisability 21 Discuss the generalisability (external validity) of the study 
results  
Other information 
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on 
which the present article is based  
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
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http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at 
http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
 
